1. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. (February 2019) Authors: Gadgeel, Shirish M.; Lukas, Rimas V.; Goldschmidt, Jerome; Conkling, Paul; Park, Keunchil; Cortinovis, Diego; de Marinis, Filippo; Rittmeyer, Achim; Patel, Jyoti D.; von Pawel, Joachim; O'Hear, Carol; Lai, Catherine; Hu, Sylvia; Ballinger, Marcus; Sandler, Alan; Gandhi, Mayank; Fehrenbacher, Lou Journal: Lung cancer Issue: Volume 128(2019) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Issue 10030 (30th April 2016) Authors: Fehrenbacher, Louis; Spira, Alexander; Ballinger, Marcus; Kowanetz, Marcin; Vansteenkiste, Johan; Mazieres, Julien; Park, Keunchil; Smith, David; Artal-Cortes, Angel; Lewanski, Conrad; Braiteh, Fadi; Waterkamp, Daniel; He, Pei; Zou, Wei; Chen, Daniel S; Yi, Jing; Sandler, Alan; Rittmeyer, Achim Journal: Lancet Issue: Volume 387:Issue 10030(2016) Page Start: 1837 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Issue 10066 (21st January 2017) Authors: Rittmeyer, Achim; Barlesi, Fabrice; Waterkamp, Daniel; Park, Keunchil; Ciardiello, Fortunato; von Pawel, Joachim; Gadgeel, Shirish M; Hida, Toyoaki; Kowalski, Dariusz M; Dols, Manuel Cobo; Cortinovis, Diego L; Leach, Joseph; Polikoff, Jonathan; Barrios, Carlos; Kabbinavar, Fairooz; Frontera, Osva... Journal: Lancet Issue: Volume 389:Issue 10066(2017) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CtDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. (2021) Authors: Zou, Wei; Yaung, Stephanie J.; Fuhlbrück, Frederike; Ballinger, Marcus; Peters, Eric; Palma, John F.; Shames, David S.; Gandara, David; Jiang, Yuqiu; Patil, Namrata S. Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Issue 1 (25th August 2021) Authors: Wu, Benjamin; Sternheim, Nitzan; Agarwal, Priya; Suchomel, Julia; Vadhavkar, Shweta; Bruno, Rene; Ballinger, Marcus; Bernaards, Coen A.; Chan, Phyllis; Ruppel, Jane; Jin, Jin; Girish, Sandhya; Joshi, Amita; Quarmby, Valerie Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Issue 1 (28th September 2021) Authors: Peters, Solange; Galle, Peter R.; Bernaards, Coen A.; Ballinger, Marcus; Bruno, René; Quarmby, Valerie; Ruppel, Jane; Vilimovskij, Alexandr; Wu, Benjamin; Sternheim, Nitzan; Reck, Martin Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. Issue 3 (18th March 2021) Authors: Gandara, David; Reck, Martin; Moro-Sibilot, Denis; Mazieres, Julien; Gadgeel, Shirish; Morris, Stefanie; Cardona, Andres; Mendus, Diana; Ballinger, Marcus; Rittmeyer, Achim; Peters, Solange Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. IRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Issue 3 (March 2017) Authors: Seymour, Lesley; Bogaerts, Jan; Perrone, Andrea; Ford, Robert; Schwartz, Lawrence H; Mandrekar, Sumithra; Lin, Nancy U; Litière, Saskia; Dancey, Janet; Chen, Alice; Hodi, F Stephen; Therasse, Patrick; Hoekstra, Otto S; Shankar, Lalitha K; Wolchok, Jedd D; Ballinger, Marcus; Caramella, Caroline; d... Journal: Lancet oncology Issue: Volume 18:Issue 3(2017:Mar.) Page Start: e143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. Issue 1 (12th September 2019) Authors: Fehlings, Michael; Jhunjhunwala, Suchit; Kowanetz, Marcin; O'Gorman, William E.; Hegde, Priti S.; Sumatoh, Hermi; Lee, Boon Heng; Nardin, Alessandra; Becht, Etienne; Flynn, Susan; Ballinger, Marcus; Newell, Evan W.; Yadav, Mahesh Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Melanoma and immunotherapy bridge 2015. Issue 1 (July 2016) Authors: Nanda, Vashisht; Peng, Weiyi; Hwu, Patrick; Davies, Michael; Ciliberto, Gennaro; Fattore, Luigi; Malpicci, Debora; Aurisicchio, Luigi; Ascierto, Paolo; Croce, Carlo; Mancini, Rita; Spranger, Stefani; Gajewski, Thomas; Wang, Yangyang; Ferrone, Soldano; Vanpouille-Box, Claire; Wennerberg, Erik; Pil... Journal: Journal of translational medicine Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗